Mirum Pharmaceuticals, Inc.·4

Mar 17, 7:30 PM ET

Ramasastry Saira 4

4 · Mirum Pharmaceuticals, Inc. · Filed Mar 17, 2026

Research Summary

AI-generated summary of this filing

Updated

Mirum (MIRM) Director Ramasastry Saira Exercises Options, Sells 2,000 Shares

What Happened

  • Director Ramasastry Saira exercised vested stock options and sold the resulting shares on 2026-03-16. She exercised 2,000 options at $23.51/share (cost $47,020) and sold 2,000 common shares in the open market at $90.76/share for $181,520. A related derivative line shows a 2,000-share conversion/disposition at $0, reflecting the option conversion/settlement. Net proceeds (sale less exercise cost) were roughly $134,500 before taxes and fees.
  • This sequence (exercise followed by immediate sale) is effectively a sale of shares rather than a new purchase.

Key Details

  • Transaction date: 2026-03-16
  • Exercise: 2,000 shares @ $23.51 = $47,020 (code M)
  • Sale: 2,000 shares @ $90.76 = $181,520 (code S)
  • Derivative conversion/disposition: 2,000 @ $0 (code M) — reflects option conversion/settlement
  • Shares owned after transaction: Not specified in the provided filing excerpt
  • Footnotes: Transaction occurred pursuant to a Rule 10b5-1 plan adopted Sept 18, 2025 (F1); the options were fully vested (F2)
  • Filing timeliness: Report filed 2026-03-17 for a 2026-03-16 transaction — appears timely (Form 4s must be filed within two business days)

Context

  • For retail investors: this was a cash exercise of vested options followed by an immediate open-market sale (commonly called a cashless or sell-to-cover pattern), which results in realized proceeds for the insider. Such sales can be routine (e.g., liquidity or tax needs) and do not by themselves indicate management’s view of the company’s long-term prospects.

Insider Transaction Report

Form 4
Period: 2026-03-16
Transactions
  • Exercise/Conversion

    Common Stock

    2026-03-16$23.51/sh+2,000$47,0202,000 total
  • Sale

    Common Stock

    [F1]
    2026-03-16$90.76/sh2,000$181,5200 total
  • Exercise/Conversion

    Stock Option (right to buy)

    [F2]
    2026-03-162,0004,000 total
    Exercise: $23.51Exp: 2032-06-01Common Stock (2,000 underlying)
Footnotes (2)
  • [F1]Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on September 18, 2025.
  • [F2]The stock option is fully vested.
Signature
/s/ Judit Ryvkin, Attorney-in-Fact|2026-03-17

Documents

1 file
  • 4
    form4-03172026_070313.xmlPrimary